Positron Emission Tomography/Computed Tomography in Esophageal Carcinoma: Applications and Limitations

Squamous cell carcinoma and adenocarcinoma represent approximately 98% of esophageal malignant tumors. During the last 30 years, the incidence of adenocarcinoma has increased in Western countries (including the USA) where adenocarcinoma currently represents more than 60% of esophageal malignancies, although, worldwide, squamous cell carcinoma continues to be the predominant histologic type. Integrated positron emission tomography or computed tomography with 2-Efluorine181 fluro-2-deoxy-o-glucose is used in many institutions routinely as a tool in the initial staging and then repeated after therapy for the assessment of response to neoadjuvant therapy and detection of recurrent disease in patients with esophageal carcinoma. As with any other imaging modality, 2-[fluorine18] fluro-2-deoxy-D-glucose-positron emission tomography or computed tomography has strengths and limitations that should be understood in order to maximize its utility. (C) 2017 Elsevier Inc. All rights reserved.